Description: (S)-Ceralasertib, the S-enantiomer of Ceralasertib (also known as AZD6738), is a novel, potent and orally bioavailable morpholino-pyrimidine-based, and selective inhibitor of the ATR (ataxia telangiectasia and rad3 related) kinase with IC50 of 2.5 nM. ATR is a serine/threonine protein kinase that is upregulated in various cancer cells, it plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress. AZD6738 has potential anticancer activity against non-small cell lung cancer (NSCLC). AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1, which prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. AZD6738 also sensitizes tumor cells to chemo-(e,g, cisplatin) and radiotherapy.

References: Lancet. 2015 Feb 26;385 Suppl 1:S58; Sci Rep. 2015 Aug 27;5:13545.

Related CAS:1352280-98-8 (formic acid); 1352226-97-1 (racemate)

纯度：≥98%

CAS：1352226-87-9